Publication | Closed Access

Roflupram, a novel phosphodiesterase 4 inhibitor, inhibits lipopolysaccharide-induced neuroinflammatory responses through activation of the AMPK/Sirt1 pathway

InflammationAnti-inflammatorySignal TransductionBiochemistryNovel Phosphodiesterase 4MedicineAutophagyImmunologyCell DeathAmpk/sirt1 PathwayNeuropharmacologyMechanism Of ActionLipopolysaccharide-induced Neuroinflammatory ResponsesPharmacologyCell SignalingProtein PhosphorylationNeuropeptidesNeuroinflammation